Quris-AI will integrate Nortis's pioneering Kidney-on-Chip technology, already vetted by the National Center for Advancing Translational Sciences (NCATS) under the National Institutes of Health ...

Quris-AI, a pioneer in AI drug safety, developed the world’s first Bio-AI clinical prediction platform, which makes drug development faster and more efficient, and promises to save hundreds of ...

Quris-AI to Provide Safety Assessments for Small Molecule Drug Candidates Before Initiating Clinical TrialsBOSTON and TEL-AVIV, Israel, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Quris-AI, an artificial ...

Here's the 15-slide presentation Quris used to raise a $9 million seed round to test the safety of drugs on miniature chips. Quris wants to find a faster way to determine which experimental drugs ...

Quris' model is to use AI-powered miniaturized "patients-on-a-chip" to avoid the risks and costs of failed clinical trials and eliminate the reliance on animal testing. In partnership with The New ...

Quris' board also includes Moderna co-founder and Massachusetts Institute of Technology (MIT) professor Robert Langer, a specialist in tissue engineering and regenerative medicine.

Quris is a promising startup that has developed AI-powered “patient-on-a-chip” system that provides an alternative to human clinical trials and animal testing in drug development.

Quris, an artificial intelligence (AI) innovator in the pharmaceutical arena, has secured an additional $9 million in seed funding, expanding its total seed round funding to $37 million.